Measuring treatment satisfaction in patients with primary immunodeficiency diseases receiving lifelong immunoglobulin replacement therapy

2005 ◽  
Vol 14 (7) ◽  
pp. 1683-1691 ◽  
Author(s):  
U. Nicolay ◽  
S. Haag ◽  
F. Eichmann ◽  
S. Herget ◽  
D. Spruck ◽  
...  
Keyword(s):  
Replacement Therapy ◽  
Primary Immunodeficiency ◽  
Treatment Satisfaction ◽  
Primary Immunodeficiency Diseases ◽  
Immunodeficiency Diseases ◽  
Immunoglobulin Replacement Therapy ◽  
Immunoglobulin Replacement

scholarly journals Intravenous Immunoglobulin Replacement Therapy in Children with Primary Immunodeficiency Diseases: A Nurse's Guide

2018 ◽  
Vol 2 (2) ◽  
pp. 149-156
Author(s):  
Ana Marija Hošnjak ◽  
Snježana Čukljek ◽  
Sanja Ledinski Fičko ◽  
Martina Smrekar ◽  
Nikolina Veriga ◽  
...  
Keyword(s):  
Replacement Therapy ◽  
Intravenous Immunoglobulin ◽  
Primary Immunodeficiency ◽  
Primary Immunodeficiency Diseases ◽  
Immunodeficiency Diseases ◽  
Immunoglobulin Replacement Therapy ◽  
Immunoglobulin Replacement

Carimune NF Liquid is a Safe and Effective Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency Diseases

2007 ◽  
Vol 27 (5) ◽  
pp. 503-509 ◽  
Author(s):  
Melvin Berger ◽  
Charlotte Cunningham-Rundles ◽  
Francisco A Bonilla ◽  
Isaac Melamed ◽  
Johann Bichler ◽  
...  
Keyword(s):  
Replacement Therapy ◽  
Primary Immunodeficiency ◽  
Primary Immunodeficiency Diseases ◽  
Immunodeficiency Diseases ◽  
Immunoglobulin Replacement Therapy ◽  
Immunoglobulin Replacement

Immunoglobulin replacement for primary immunodeficiency: Indications for initiating and continuing treatment

2021 ◽  
Vol 42 (6) ◽  
pp. 489-494 ◽  
Author(s):  
Richard L. Wasserman
Keyword(s):  
Replacement Therapy ◽  
Primary Immunodeficiency ◽  
New Products ◽  
Relevant Literature ◽  
Clinical History ◽  
Laboratory Evaluation ◽  
Burden Of Care ◽  
Continue Treatment ◽  
Immunoglobulin Replacement Therapy ◽  
Immunoglobulin Replacement

Background: Immunoglobulin replacement therapy (IGRT) is the foundation of treatment for the majority of patients with primary immunodeficiency. Clinical history and laboratory evaluation define the patients for whom IGRT is necessary and appropriate. During the 70 years since the first patient was treated, new products have led to the development of several modes of administration that facilitate the individualization of treatment that enables the optimization of care. Objective: The objective was to explain the assessment of candidates for IGRT and approaches to reevaluating recipients of IGRT to decide on the need to continue treatment and to review the approaches to optimize IGRT. Methods: The relevant literature was reviewed in the context of the author's experience supervising > 20,000 IGRT treatments over a 40-year period. Results: Providing the most appropriate form of IGRT for individual patients ameliorates disease and lessens the burden of care for patients with primary immunodeficiency. Conclusion: IGRT is safe and effective when used to treat patients with primary immunodeficiency who meet established and appropriate clinical and laboratory criteria.

scholarly journals Primary immunodeficiency diseases treated with immunoglobulin and associated comorbidities

2021 ◽  
Vol 42 (1) ◽  
pp. 78-86 ◽  
Author(s):  
Michelle Dilley ◽  
Hannah Wangberg ◽  
Joshua Noone ◽  
Bob Geng
Keyword(s):  
Primary Immunodeficiency ◽  
Deficiency Anemia ◽  
Chronic Obstructive ◽  
Comorbid Conditions ◽  
Primary Immunodeficiency Diseases ◽  
Electrolyte Disorders ◽  
Age Cohorts ◽  
Immunodeficiency Diseases ◽  
Increased Risk ◽  
Immunoglobulin Replacement

Background: Primary immunodeficiency diseases (PIDD) consist of a heterogeneous group of disorders characterized by various aspects of immune dysregulation. Although the most universally recognized manifestation of PIDD is an increased susceptibility to infections, there is a growing body of evidence that patients with PIDD often have a higher incidence of lung disease, autoimmunity, autoinflammatory disorders, and malignancy. Objective: The purpose of this study was to better understand the noninfectious complications of PIDD by determining the comorbid disease prevalence across various age groups, genders, and immunoglobulin replacement types compared with the general population. Methods: A large U.S. insurance claims database was retrospectively analyzed for patients who had a diagnosis of PIDD and who had received intravenous immunoglobulin (IVIG) or subcutaneous immunoglobulin (SCIG). The prevalences of 31 different comorbid conditions in the Elixhauser comorbidity index were compared among the 3125 patients in the PIDD population to > 37 million controls separated by gender and by 10-year age cohorts. Results: In the PIDD population, statistically significantly higher comorbid diagnoses included chronic obstructive pulmonary disease‐asthma in 51.5%, rheumatoid disease in 14%, deficiency anemia in 11.8%, hypothyroidism in 21.2%, lymphoma in 16.7%, neurologic disorders in 9.7%, arrhythmias in 19.9%, electrolyte disorders in 23.6%, coagulopathies in 16.9%, and weight loss in 8.4%. Conclusion: PIDD that require immunoglobulin replacement are associated with an increased risk of numerous comorbid conditions that affect morbidity and mortality. Recognition and increased awareness of these noninfectious complications can allow for better monitoring, care coordination, targeted treatments, and improved prognosis.

Sign in / Sign up

Export Citation Format

Share Document